Get the Stockscreener App
205.02
0.99%
2.01
Pre-market:
205.83
0.81
+0.40%
Overview
News
Price History
Option Chain
Financials
Why ABBV Down?
Discussions
Forecast
Dividend History
Abbvie Inc stock is traded at $205.02, with a volume of 5.61M.
It is up +0.99% in the last 24 hours and up +15.90% over the past month.
AbbVie is a pharmaceutical firm with a strong exposure to immunology (with Humira, Skyrizi, and Rinvoq) and oncology (with Imbruvica and Venclexta). The company was spun off from Abbott in early 2013. The 2020 acquisition of Allergan added several new products and drugs in aesthetics (including Botox).
See More
Previous Close:
$203.01
Open:
$203.06
24h Volume:
5.61M
Relative Volume:
1.05
Market Cap:
$361.93B
Revenue:
$56.33B
Net Income/Loss:
$4.28B
P/E Ratio:
85.43
EPS:
2.4
Net Cash Flow:
$17.83B
1W Performance:
+2.06%
1M Performance:
+15.90%
6M Performance:
+4.64%
1Y Performance:
+14.54%
1-Day Range:
$202.25
$206.80
1-Week Range:
$200.01
$206.80
52-Week Range:
$153.58
$207.32
Abbvie Inc Stock (ABBV) Company Profile
Name
Abbvie Inc
Sector
Industry
Phone
(847) 932-7900
Address
1 NORTH WAUKEGAN ROAD, NORTH CHICAGO, IL
Compare ABBV with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ABBV
Abbvie Inc
|
205.02 | 361.93B | 56.33B | 4.28B | 17.83B | 2.40 |
|
LLY
Lilly Eli Co
|
905.16 | 860.27B | 45.04B | 10.59B | 414.30M | 11.71 |
|
NVO
Novo Nordisk Adr
|
89.22 | 396.05B | 42.09B | 14.65B | 10.11B | 3.2833 |
|
JNJ
Johnson Johnson
|
163.73 | 344.63B | 88.82B | 14.07B | 18.06B | 5.79 |
|
MRK
Merck Co Inc
|
90.58 | 251.88B | 64.17B | 17.12B | 18.10B | 6.73 |
Abbvie Inc Stock (ABBV) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-10-24 | Resumed | BofA Securities | Neutral |
| Dec-05-24 | Downgrade | Daiwa Securities | Outperform → Neutral |
| Nov-22-24 | Upgrade | Leerink Partners | Market Perform → Outperform |
| Nov-15-24 | Initiated | Wolfe Research | Outperform |
| Nov-04-24 | Upgrade | Argus | Hold → Buy |
| Oct-17-24 | Initiated | Bernstein | Mkt Perform |
| Jun-05-24 | Upgrade | HSBC Securities | Hold → Buy |
| May-17-24 | Initiated | Cantor Fitzgerald | Overweight |
| Jan-29-24 | Upgrade | William Blair | Mkt Perform → Outperform |
| Dec-18-23 | Downgrade | HSBC Securities | Buy → Hold |
| Dec-11-23 | Upgrade | Goldman | Neutral → Buy |
| Nov-09-23 | Initiated | Deutsche Bank | Hold |
| Oct-30-23 | Upgrade | Barclays | Equal Weight → Overweight |
| Oct-20-23 | Resumed | UBS | Neutral |
| Sep-29-23 | Initiated | Raymond James | Outperform |
| Jul-25-23 | Initiated | William Blair | Mkt Perform |
| Jul-14-23 | Initiated | HSBC Securities | Buy |
| Apr-05-23 | Downgrade | Argus | Buy → Hold |
| Mar-01-23 | Initiated | Guggenheim | Buy |
| Feb-22-23 | Downgrade | Wolfe Research | Outperform → Peer Perform |
| Feb-10-23 | Upgrade | SVB Securities | Underperform → Market Perform |
| Nov-18-22 | Initiated | Credit Suisse | Outperform |
| Nov-08-22 | Downgrade | Societe Generale | Buy → Hold |
| Aug-01-22 | Downgrade | Atlantic Equities | Overweight → Neutral |
| May-23-22 | Initiated | SVB Leerink | Underperform |
| May-06-22 | Downgrade | Daiwa Securities | Outperform → Neutral |
| Apr-06-22 | Resumed | Morgan Stanley | Overweight |
| Feb-28-22 | Downgrade | UBS | Buy → Neutral |
| Feb-03-22 | Reiterated | BMO Capital Markets | Outperform |
| Feb-03-22 | Reiterated | Barclays | Equal Weight |
| Feb-03-22 | Reiterated | BofA Securities | Neutral |
| Feb-03-22 | Reiterated | Goldman | Neutral |
| Jan-13-22 | Initiated | Redburn | Buy |
| Jan-12-22 | Reiterated | BMO Capital Markets | Outperform |
| Dec-09-21 | Resumed | Wells Fargo | Overweight |
| Nov-23-21 | Upgrade | Societe Generale | Hold → Buy |
| Jul-27-21 | Resumed | Truist | Buy |
| Apr-07-21 | Resumed | RBC Capital Mkts | Outperform |
| Nov-10-20 | Resumed | Bernstein | Outperform |
| Sep-29-20 | Initiated | Berenberg | Hold |
| Jun-23-20 | Upgrade | Atlantic Equities | Neutral → Overweight |
| Jun-09-20 | Upgrade | Wolfe Research | Peer Perform → Outperform |
| Jun-02-20 | Upgrade | Argus | Hold → Buy |
| May-18-20 | Resumed | BofA/Merrill | Neutral |
| May-12-20 | Upgrade | JP Morgan | Neutral → Overweight |
| May-11-20 | Resumed | Morgan Stanley | Overweight |
| Apr-20-20 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Mar-23-20 | Downgrade | Societe Generale | Buy → Hold |
| Feb-27-20 | Initiated | Barclays | Equal Weight |
| Feb-06-20 | Initiated | Mizuho | Buy |
| Jan-07-20 | Initiated | RBC Capital Mkts | Sector Perform |
| Dec-26-19 | Reiterated | Cowen | Outperform |
| Sep-26-19 | Upgrade | Citigroup | Neutral → Buy |
| Aug-20-19 | Upgrade | Piper Jaffray | Neutral → Overweight |
| Jun-27-19 | Upgrade | Wolfe Research | Underperform → Peer Perform |
| Jun-26-19 | Upgrade | SVB Leerink | Mkt Perform → Outperform |
| May-28-19 | Initiated | Goldman | Neutral |
| Apr-29-19 | Upgrade | BMO Capital Markets | Underperform → Market Perform |
View All
Abbvie Inc Stock (ABBV) Latest News
AbbVie closes on Rinvoq approval in inflamed artery disease - pharmaphorum
AbbVie Receives Positive Opinion on Giant Cell Arteritis Therapy From European Medicines Agency - Marketscreener.com
U.S. Acellular Dermal Matrices Market Projected To Witness Substantial Growth, 2025-2032: AbbVie Inc., Johnson - EIN News
AbbVie Receives Positive CHMP Opinion for Upadacitinib (RINVOQ®) for the Treatment of Adults with Giant Cell Arteritis - PR Newswire
ABBV: 3 Healthcare Stocks Tackling America’s Biggest Medical Challenges - StockNews.com
Mustang Bio exits Worcester facility, sells assets to AbbVie By Investing.com - Investing.com South Africa
Mustang Bio exits Worcester facility, sells assets to AbbVie - Investing.com
Want Decades of Passive Income? 3 Stocks to Buy Now and Hold Forever - The Motley Fool
AbbVie completes $4 billion senior notes offering - Investing.com India
Endometriosis Market Predicted to See Upsurge Through 2034, - openPR
AbbVie Inc. (ABBV) Is a Trending Stock: Facts to Know Before Betting on It - Nasdaq
Africa Injectable Drugs Market Projected To Witness Substantial Growth 2025-2032: Merck & Co. Inc., AbbVie - EIN News
Is AbbVie Inc. (ABBV) the Best DRIP Stock to Own Now? - Insider Monkey
Investors Don't See Light At End Of AbbVie Inc.'s (NYSE:ABBV) Tunnel - Simply Wall St
AbbVie R&D expenditure 2012-2024 - Statista
Hormonal Contraceptive Market: Demand and Competitive Landscape | Abbvie Inc, Afaxys Inc - openPR
Abbvie executive Perry C. Siatis sells $1.14 million in stock - Investing.com India
AbbVie Executive Sells Shares Worth Over $1.1 Million - TradingView
Here's How Much You Would Have Made Owning AbbVie Stock In The Last 10 Years - Benzinga
AbbVie Inc. (ABBV): Among S&P 500 Dividend Aristocrats List - Insider Monkey
The Zacks Analyst Blog Highlights AbbVie, Amgen, Stryker, Dexcom and Medtronic - Nasdaq
AbbVie's Stock Rocket or Rollercoaster? Discover the AI Potential! - Mi Valle
Why AbbVie Remains A Strong Buy For Long-Term Investors (NYSE:ABBV) - Seeking Alpha
AbbVie Inc. (NYSE:ABBV) Holdings Decreased by First National Bank & Trust Co. of Newtown - MarketBeat
Gilead Sciences: 4 Reasons This Stock Has Much More To Rise - Benzinga
Some May Be Optimistic About AbbVie's (NYSE:ABBV) Earnings - Yahoo Finance
Parenteral Nutrition Market Future Business Opportunities - openPR
AbbVie Inc. (ABBV) Stock: Pharmaceutical Sector Investment Option - INDODAX
Xilio (XLO) Stock Zooms 125% Higher On Cancer Fighting Deal with AbbVie - MSN
AbbVie Inc. (ABBV) Announces $4 Billion Senior Notes Offering - GuruFocus.com
Real-World Evidence in IBD: Driving Innovative Approaches to Care - AbbVie
AbbVie Appears Ready To Move Higher - Seeking Alpha
Xilio Therapeutics’ $2.1 Billion Collaboration With AbbVie - Global Legal Chronicle
Abbvie Inc. Reports 9.0 % Passive Stake In Xilio Therapeutics, Inc. As Of Feb 11SEC Filing - Marketscreener.com
Is AbbVie Stock a Buy Now? - MSN
ABBV Quantitative Stock Analysis - Nasdaq
Beyond the Possible: How AbbVie Uses Technology to Transform Medicines for Patients - CBS News
How Is The Market Feeling About AbbVie? - Benzinga
ABBV: 3 Dividend Growth Stocks for Long-Term Wealth - StockNews.com
Why AbbVie Inc. (ABBV) Is One of the Best Drug Stocks to Buy Now - Insider Monkey
Aseptic Fill Finish Market Top Companies StudyAenova, AbbVie - openPR
10 Best Drug Stocks to Buy Now - Insider Monkey
AbbVie Full Year 2024 Earnings: EPS Misses Expectations - Yahoo Finance
Focus Financial Network Inc. Trims Stake in AbbVie Inc. (NYSE:ABBV) - MarketBeat
Roxbury Financial LLC Invests $496,000 in AbbVie Inc. (NYSE:ABBV) - MarketBeat
AbbVie Inc. (NYSE:ABBV) Shares Sold by Rhumbline Advisers - MarketBeat
BXM Wealth LLC Takes Position in AbbVie Inc. (NYSE:ABBV) - MarketBeat
Autumn Glory Partners LLC Lowers Position in AbbVie Inc. (NYSE:ABBV) - MarketBeat
Blue Trust Inc. Buys 8,959 Shares of AbbVie Inc. (NYSE:ABBV) - MarketBeat
WealthPLAN Partners LLC Lowers Stock Holdings in AbbVie Inc. (NYSE:ABBV) - MarketBeat
Adell Harriman & Carpenter Inc. Buys 2,721 Shares of AbbVie Inc. (NYSE:ABBV) - MarketBeat
Abbvie Inc Stock (ABBV) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.40%
0.37%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):